Parkside Financial Bank & Trust Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Parkside Financial Bank & Trust lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 1.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,922 shares of the conglomerate’s stock after selling 77 shares during the period. Parkside Financial Bank & Trust’s holdings in Danaher were worth $980,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after buying an additional 1,533 shares during the last quarter. Caden Capital Partners LP grew its stake in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after purchasing an additional 15,313 shares during the last quarter. JARISLOWSKY FRASER Ltd increased its holdings in shares of Danaher by 10.8% in the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after purchasing an additional 55,908 shares during the period. HighPoint Advisor Group LLC acquired a new stake in shares of Danaher during the fourth quarter worth $2,614,000. Finally, Norden Group LLC purchased a new position in Danaher in the 1st quarter valued at $4,151,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

DHR traded up $2.81 during midday trading on Friday, reaching $267.52. 562,414 shares of the company’s stock were exchanged, compared to its average volume of 2,774,937. The business’s 50-day moving average price is $260.98 and its 200 day moving average price is $255.61. The stock has a market capitalization of $198.15 billion, a PE ratio of 45.52, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 EPS. As a group, equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research report on Friday. Bank of America increased their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Robert W. Baird increased their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.